Similar articles for PMID: 26742708

Year	Number of Results
1878	1
1901	1
1947	1
1950	2
1952	2
1953	3
1954	1
1955	1
1956	1
1963	2
1980	1
1981	1
1982	1
1987	3
1988	1
1989	3
1990	1
1992	4
1993	1
1994	1
1995	6
1996	1
1997	2
1998	7
1999	9
2000	12
2001	11
2002	6
2003	10
2004	10
2005	6
2006	5
2007	6
2008	13
2009	8
2010	7
2011	14
2012	17
2013	23
2014	12
2015	16
2016	18
2017	22
2018	19
2019	12
2020	15
2021	24
2022	24
2023	9
2024	0

1

Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.

Modak S, Zanzonico P, Carrasquillo JA, Kushner BH, Kramer K, Cheung NK, Larson SM, Pandit-Taskar N. Modak S, et al. J Nucl Med. 2016 Feb;57(2):231-7. doi: 10.2967/jnumed.115.161752. Epub 2016 Jan 7. J Nucl Med. 2016. PMID: 26742708 Free PMC article. Clinical Trial.

2

Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.

Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J. Matthay KK, et al. J Nucl Med. 2012 Jul;53(7):1155-63. doi: 10.2967/jnumed.111.098624. Epub 2012 Jun 14. J Nucl Med. 2012. PMID: 22700000 Free article.

3

Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).

Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, Dela Cruz F, Jahan TM, Linker CA, Damon L, Matthay KK. Fitzgerald PA, et al. Ann N Y Acad Sci. 2006 Aug;1073:465-90. doi: 10.1196/annals.1353.050. Ann N Y Acad Sci. 2006. PMID: 17102115 Clinical Trial.

4

Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.

Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S, Fitzgerald P. Gonias S, et al. J Clin Oncol. 2009 Sep 1;27(25):4162-8. doi: 10.1200/JCO.2008.21.3496. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636009 Free PMC article. Clinical Trial.

5

High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.

Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA, Fitzgerald PA. Rose B, et al. Cancer. 2003 Jul 15;98(2):239-48. doi: 10.1002/cncr.11518. Cancer. 2003. PMID: 12872341 Free article.

6

[Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].

Défachelles AS, Cougnenc O, Carpentier P. Défachelles AS, et al. Bull Cancer. 2011 May;98(5):559-69. doi: 10.1684/bdc.2011.1353. Bull Cancer. 2011. PMID: 21609890 Free article. Review. French.

7

[(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts.

Rutgers M, Buitenhuis CK, van der Valk MA, Hoefnagel CA, Voûte PA, Smets LA. Rutgers M, et al. Int J Cancer. 2000 Dec 20;90(6):312-25. Int J Cancer. 2000. PMID: 11180134 Free article.

8

Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.

Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, Hawkins RA, Veatch J, Hasegawa B. Matthay KK, et al. J Nucl Med. 2001 Nov;42(11):1713-21. J Nucl Med. 2001. PMID: 11696644 Free article. Clinical Trial.

9

A phase I clinical trial for [¹³¹I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma: a study protocol.

Inaki A, Yoshimura K, Murayama T, Imai Y, Kuribayashi Y, Higuchi T, Jinguji M, Shiga T, Kinuya S. Inaki A, et al. J Med Invest. 2017;64(3.4):205-209. doi: 10.2152/jmi.64.205. J Med Invest. 2017. PMID: 28954983 Free article. Clinical Trial.

10

Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.

Yoshinaga K, Oriuchi N, Wakabayashi H, Tomiyama Y, Jinguji M, Higuchi T, Kayano D, Fukuoka M, Inaki A, Toratani A, Okamoto S, Shiga T, Ito YM, Nakajo M, Nakajo M, Kinuya S; Drafting Committee for Guidelines on Internal Radiotherapy with ¹³¹I-MIBG; Japanese Society of Nuclear Medicine in Oncology and Imunology; Japanese Society of Nuclear Medicine. Yoshinaga K, et al. Endocr J. 2014;61(12):1171-80. doi: 10.1507/endocrj.EJ14-0211. Epub 2014 Sep 11. Endocr J. 2014. PMID: 25214026 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

343 results

Results by year